menu
    • menu
    [{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carrick Therapeutics \/ Arvinas","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Arvinas"}]

    Find Clinical Drug Pipeline Developments & Deals for Samuraciclib

    Menu

    Samuraciclib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samuraciclib,Vepdegestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Carrick Doses First Patient in Phase 1b/2 Trial of Samuraciclib in Breast Cancer

                            Details : CT7001 (samuraciclib) is a first-in-class oral CDK7 inhibitor evaluated with ARV-471 (vepdegestrant) for ER+, HER2- metastatic breast cancer treatment.

                            Product Name : CT7001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 14, 2024

                            Lead Product(s) : Samuraciclib,Vepdegestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination w...

                            Details : Samuraciclib (CT7001) - an oral CDK7 inhibitor in combination with Fulvestrant is being evaluated in phase 2 clinical trials for the treatment of HER2- advanced breast cancer.

                            Product Name : CT7001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 15, 2023

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samuraciclib,Elacestrant DiHCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination wi...

                            Details : CT7001 (samuraciclib) is an oral and first-in-class inhibitor of CDK7, and the Menarini Group's (Menarini) oral selective estrogen receptor degrader (SERD), elacestrant, in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer.

                            Product Name : CT7001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 18, 2023

                            Lead Product(s) : Samuraciclib,Elacestrant DiHCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Arvinas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib a...

                            Details : TWYNEO is a topical cream containing a fixed‑dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.

                            Product Name : CT7001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 07, 2023

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Arvinas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Carrick Therapeutics

                            Ireland arrow
                            Interphex
                            Not Confirmed

                            Carrick Therapeutics

                            Ireland arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Carrick Therapeutics Announces $35 Million Investment from Pfizer

                            Details : CT7001 (samuraciclib), an oral CDK7 inhibitor, is a promising therapeutic strategy in cancer, as CDK7 regulates transcription of cancer-causing genes and promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy.

                            Product Name : CT7001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 12, 2022

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Arch Ventures

                            Deal Size : $25.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Carrick Therapeutics Closes Series C Financing

                            Details : The Company intends to use the proceeds to fund ongoing and planned CT7001 (samuraciclib) clinical trials, ongoing development of its CDK12/13 inhibitor / Cyclin-K glue-degrader, and for working capital and general corporate purposes.

                            Product Name : CT7001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 12, 2022

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Arch Ventures

                            Deal Size : $25.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Carrick Therapeutics Announces $35 Million Investment from Pfizer

                            Details : Under the terms of the agreement, Pfizer will provide global development capabilities and expertise to support Carrick’s Phase 2 study of CT-7001 (samuraciclib) in combination with fulvestrant for CDK4/6i-resistant HR+, HER2- advanced breast cancer.

                            Product Name : CT7001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 12, 2022

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Carrick Therapeutics to Present Clinical Data on Samuraciclib (CT7001), a First-In-Class Inhibitor of CDK7, at...

                            Details : Samuraciclib inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy.

                            Product Name : CT7001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 22, 2021

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulv...

                            Details : Samuraciclib (CT-7001), an oral and first-in-class inhibitor of CDK7, used in combination with fulvestrant demonstrated clinical activity and tolerability in patients with HR+, HER2- advanced breast cancer.

                            Product Name : CT7001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 16, 2021

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed

                            Carrick Therapeutics

                            Ireland arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001) at the 2021 San Antonio Brea...

                            Details : Clinical data on samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, regulates the transcription of cancer-causing genes,support its continued development in breast cancer.

                            Product Name : CT7001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 12, 2021

                            Lead Product(s) : Samuraciclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth